SCHEMBL8307331

SCHEMBL8307331

[O]CCNCCN1CCCCC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CARM1 Q86X55 1/20 0.48
PRMT6 Q96LA8 1/20 0.48
PRMT8 Q9NR22 1/20 0.48
SIGMAR1 Q99720 5/20 0.47
ACE2 Q9BYF1 1/20 0.46
CA12 O43570 3/20 0.44
CA1 P00915 3/20 0.44
CA2 P00918 3/20 0.44
CA9 Q16790 3/20 0.44
DPP7 Q9UHL4 1/20 0.44
HRH3 Q9Y5N1 1/20 0.42
CYP1A2 P05177 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
NPC1 O15118 1/20 0.41
KDM1A O60341 1/20 0.41
MAPT P10636 2/20 0.40
ALDH1A1 P00352 1/20 0.40
POLB P06746 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8306447 0.98 CARM1 (0.50) CARM1PRMT6PRMT8SIGMAR1ACE2
SCHEMBL4288469 0.88 CARM1 (0.59) CARM1PRMT6PRMT8SIGMAR1ACE2
SCHEMBL31326654 0.88 CARM1 (0.59) CARM1PRMT6PRMT8SIGMAR1ACE2
SCHEMBL8310041 0.87 ACE2 (0.48) CARM1PRMT6PRMT8SIGMAR1ACE2
SCHEMBL8309175 0.87 HRH3 (0.50) CARM1PRMT6PRMT8ACE2CA12
SCHEMBL10410535 0.85 CARM1 (0.62) CARM1PRMT6PRMT8SIGMAR1ACE2
SCHEMBL8309991 0.84 SCN5A (0.46) CARM1PRMT6PRMT8SIGMAR1ACE2
SCHEMBL8310197 0.84 ACE2 (0.50) CARM1PRMT6PRMT8SIGMAR1ACE2
SCHEMBL22788741 0.83 CARM1 (0.59) CARM1PRMT6PRMT8SIGMAR1ACE2
SCHEMBL17528553 0.83 CARM1 (0.59) CARM1PRMT6PRMT8SIGMAR1ACE2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11964953-B2 Substituted aminothiazoles as DGKzeta inhibitors for immune activation BAYER AKTIENGESELLSCHAFT (DE) 2024-04-23 US disclosed
US-20230167078-A1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION BAYER AKTIENGESELLSCHAFT (DE) 2023-06-01 US disclosed
EP-0790986-B1 ANILINE DERIVATIVES ZENECA LTD (GB) 1999-01-20 EP disclosed
EP-0790986-A1 ANILINE DERIVATIVES ZENECA LIMITED (GB) 1997-08-27 EP disclosed
WO-1996015118-A1 ANILINE DERIVATIVES ZENECA LIMITED (GB) 1996-05-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230167078-A1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION DGKZ, DGKA, DGKG CARM1 2153/4885PRMT6 754/4885PRMT8 1044/4885
US-11964953-B2 Substituted aminothiazoles as DGKzeta inhibitors for immune activation DGKZ, DGKA, DGKG CARM1 2153/4885PRMT6 754/4885PRMT8 1044/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.